The role of the multidisciplinary tumor board (MDTB) in the assessment of pancreatic cancer diagnosis and resectability: A tertiary referral center experience.

diagnosis multidisciplinary pancreatic cancer resectability treatment response

Journal

Frontiers in surgery
ISSN: 2296-875X
Titre abrégé: Front Surg
Pays: Switzerland
ID NLM: 101645127

Informations de publication

Date de publication:
2023
Historique:
received: 08 12 2022
accepted: 31 01 2023
entrez: 6 3 2023
pubmed: 7 3 2023
medline: 7 3 2023
Statut: epublish

Résumé

The introduction of multidisciplinary tumor boards (MDTBs) for the diagnostic and therapeutic pathway of several oncological disease significantly ameliorated patients' outcomes. However, only few evidences are currently present on the potential impact of the MDTB on pancreatic cancer (PC) management. Aim of this study is to report how MDTB may influence PC diagnosis and treatment, with particular focus on PC resectability assessment and the correspondence between MDTB definition of resectability and intraoperative findings. All patients with a proven or suspected diagnosis of PC discussed at the MDTB between 2018 and 2020 were included in the study. An evaluation of diagnosis, tumor response to oncological/radiation therapy and resectability before and after the MDTB was conducted. Moreover, a comparison between the MDTB resectability assessment and the intraoperative findings was performed. A total of 487 cases were included in the analysis: 228 (46.8%) for diagnosis evaluation, 75 (15.4%) for tumor response assessment after/during medical treatment, 184 (37.8%) for PC resectability assessment. As a whole, MDTB led to a change in treatment management in 89 cases (18.3%): 31/228 (13.6%) in the diagnosis group, 13/75 (17.3%) in the assessment of treatment response cohort and 45/184 (24.4%) in the PC resectability evaluation group. As a whole, 129 patients were given indication to surgery. Surgical resection was accomplished in 121 patients (93.7%), with a concordance rate of resectability between MDTB discussion and intraoperative findings of 91.5%. Concordance rate was 99% for resectable lesions and 64.3% for borderline PCs. MDTB discussion consistently influences PC management, with significant variations in terms of diagnosis, tumor response assessment and resectability. In this last regard, MDTB discussion plays a key role, as demonstrated by the high concordance rate between MDTB resectability definition and intraoperative findings.

Sections du résumé

Background UNASSIGNED
The introduction of multidisciplinary tumor boards (MDTBs) for the diagnostic and therapeutic pathway of several oncological disease significantly ameliorated patients' outcomes. However, only few evidences are currently present on the potential impact of the MDTB on pancreatic cancer (PC) management. Aim of this study is to report how MDTB may influence PC diagnosis and treatment, with particular focus on PC resectability assessment and the correspondence between MDTB definition of resectability and intraoperative findings.
Methods UNASSIGNED
All patients with a proven or suspected diagnosis of PC discussed at the MDTB between 2018 and 2020 were included in the study. An evaluation of diagnosis, tumor response to oncological/radiation therapy and resectability before and after the MDTB was conducted. Moreover, a comparison between the MDTB resectability assessment and the intraoperative findings was performed.
Results UNASSIGNED
A total of 487 cases were included in the analysis: 228 (46.8%) for diagnosis evaluation, 75 (15.4%) for tumor response assessment after/during medical treatment, 184 (37.8%) for PC resectability assessment. As a whole, MDTB led to a change in treatment management in 89 cases (18.3%): 31/228 (13.6%) in the diagnosis group, 13/75 (17.3%) in the assessment of treatment response cohort and 45/184 (24.4%) in the PC resectability evaluation group. As a whole, 129 patients were given indication to surgery. Surgical resection was accomplished in 121 patients (93.7%), with a concordance rate of resectability between MDTB discussion and intraoperative findings of 91.5%. Concordance rate was 99% for resectable lesions and 64.3% for borderline PCs.
Conclusions UNASSIGNED
MDTB discussion consistently influences PC management, with significant variations in terms of diagnosis, tumor response assessment and resectability. In this last regard, MDTB discussion plays a key role, as demonstrated by the high concordance rate between MDTB resectability definition and intraoperative findings.

Identifiants

pubmed: 36874464
doi: 10.3389/fsurg.2023.1119557
pmc: PMC9981784
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1119557

Informations de copyright

© 2023 Quero, De Sio, Fiorillo, Menghi, Rosa, Massimiani, Laterza, Lucinato, Galiandro, Papa, Salvatore, Bensi, Tortorelli, Tondolo and Alfieri.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Abdom Radiol (NY). 2018 Feb;43(2):435-444
pubmed: 29243123
Ann Surg Oncol. 2016 Aug;23(8):2430-7
pubmed: 27002814
Surg Clin North Am. 2016 Dec;96(6):1235-1256
pubmed: 27865275
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Theranostics. 2022 Oct 3;12(16):6931-6954
pubmed: 36276650
Surg Oncol Clin N Am. 2013 Apr;22(2):265-87
pubmed: 23453334
J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8
pubmed: 18471707
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Ann Surg. 2017 Aug;266(2):333-338
pubmed: 27429020
Ann Surg Oncol. 2008 Aug;15(8):2081-8
pubmed: 18461404
HPB (Oxford). 2017 Feb;19(2):133-139
pubmed: 27916436
J Am Coll Surg. 2013 Sep;217(3):412-20
pubmed: 23891067
Int J Gynecol Cancer. 2010 Nov;20(8):1321-5
pubmed: 21051971
Cancer Treat Rev. 2016 Jan;42:56-72
pubmed: 26643552
Ann Surg Oncol. 2006 Aug;13(8):1035-46
pubmed: 16865597
Ann Surg. 2007 Aug;246(2):173-80
pubmed: 17667493
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Pancreas. 2021 Aug 1;50(7):916-922
pubmed: 34629446
Eur J Cancer. 2018 Jan;88:77-86
pubmed: 29195117
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457
pubmed: 33845462
Cancers (Basel). 2020 Jun 24;12(6):
pubmed: 32599886
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Surg Innov. 2022 Jun;29(3):313-314
pubmed: 34866470
Int J Gynecol Cancer. 2004 Mar-Apr;14(2):206-9
pubmed: 15086716
Cancer. 2001 Apr 1;91(7):1231-7
pubmed: 11283921
World J Gastrointest Oncol. 2013 Mar 15;5(3):60-7
pubmed: 23671732
Int J Clin Oncol. 2013 Apr;18(2):214-9
pubmed: 22193638
ESMO Open. 2021 Feb;6(1):100010
pubmed: 33399076
Int J Surg. 2020 May;77:105-110
pubmed: 32234347

Auteurs

Giuseppe Quero (G)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.
Gemelli Pancreatic Advanced Research Center (CRMPG), Università Cattolica del Sacro Cuore di Roma, Rome, Italy.

Davide De Sio (D)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.

Claudio Fiorillo (C)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.

Roberta Menghi (R)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.
Gemelli Pancreatic Advanced Research Center (CRMPG), Università Cattolica del Sacro Cuore di Roma, Rome, Italy.

Fausto Rosa (F)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.
Gemelli Pancreatic Advanced Research Center (CRMPG), Università Cattolica del Sacro Cuore di Roma, Rome, Italy.

Giuseppe Massimiani (G)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.

Vito Laterza (V)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.

Chiara Lucinato (C)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.

Federica Galiandro (F)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.

Valerio Papa (V)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.
Gemelli Pancreatic Advanced Research Center (CRMPG), Università Cattolica del Sacro Cuore di Roma, Rome, Italy.

Lisa Salvatore (L)

Gemelli Pancreatic Advanced Research Center (CRMPG), Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.

Maria Bensi (M)

Gemelli Pancreatic Advanced Research Center (CRMPG), Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.

Antonio Pio Tortorelli (AP)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.

Vincenzo Tondolo (V)

General Surgery Unit, Fatebenefratelli Isola Tiberina - Gemelli Isola, Via di Ponte Quattro Capi, Roma, Italy.

Sergio Alfieri (S)

Pancreatic Surgery Unit, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Agostino Gemelli, Rome, Italy.
Gemelli Pancreatic Advanced Research Center (CRMPG), Università Cattolica del Sacro Cuore di Roma, Rome, Italy.

Classifications MeSH